1,024,937 Shares in Evolus, Inc. $EOLS Bought by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new position in Evolus, Inc., purchasing approximately 1,024,937 shares valued at $12.33 million, representing about 1.59% ownership of the company.
• Several large investors, including ProShare Advisors LLC and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., have recently increased their holdings in Evolus, indicating strong institutional interest.
• Evolus's stock has faced recent downgrades from analysts, with price targets being reduced; HC Wainwright cut its target from $27.00 to $20.00 while maintaining a "buy" rating.

Nuveen LLC acquired a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,024,937 shares of the company's stock, valued at approximately $12,330,000. Nuveen LLC owned about 1.59% of Evolus at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Evolus by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company's stock valued at $347,000 after acquiring an additional 1,094 shares during the last quarter. MetLife Investment Management LLC increased its position in Evolus by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock worth $378,000 after purchasing an additional 2,044 shares in the last quarter. Rhumbline Advisers increased its position in Evolus by 4.1% during the 1st quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock worth $1,004,000 after purchasing an additional 3,287 shares in the last quarter. ProShare Advisors LLC increased its position in Evolus by 31.0% during the 4th quarter. ProShare Advisors LLC now owns 18,563 shares of the company's stock worth $205,000 after purchasing an additional 4,392 shares in the last quarter. Finally, IFP Advisors Inc increased its position in Evolus by 99.0% during the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock worth $113,000 after purchasing an additional 4,691 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Insiders Place Their Bets

In other news, Director Brady Stewart acquired 30,000 shares of Evolus stock in a transaction that occurred on Friday, August 15th. The shares were purchased at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the purchase, the director directly owned 88,629 shares of the company's stock, valued at $604,449.78. This trade represents a 51.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the transaction, the chief marketing officer owned 89,949 shares in the company, valued at $675,516.99. This trade represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 133,627 shares of company stock valued at $1,325,764. Corporate insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EOLS. BTIG Research dropped their target price on shares of Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC reissued a "hold" rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. HC Wainwright dropped their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Evolus has an average rating of "Moderate Buy" and an average target price of $21.25.

Evolus Stock Down 0.9%

Shares of Evolus stock traded down $0.07 on Wednesday, hitting $7.58. 677,311 shares of the company's stock traded hands, compared to its average volume of 2,323,515. The stock has a market cap of $490.27 million, a P/E ratio of -7.73 and a beta of 1.12. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. The firm's 50-day moving average is $8.50 and its 200 day moving average is $10.52. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.82.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.